Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KVD824 in Hereditary Angioedema Type I or II
NCT05055258Phase 2Terminated
- Sponsor
- KalVista Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of KVD824 in hereditary angioedema (HAE), sponsored by KalVista Pharmaceuticals. Started Nov 2021; status: terminated.
02
Drugs
KVD824
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05055258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055258.